ONCOSEC ANNOUNCES POSTER PRESENTATION AT 2019 AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING
Data Supports New Product Candidate's Ability To Elicit Robust Anti-Tumor Activity
SAN DIEGO and PENNINGTON, N.J., Feb. 28, 2019 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing novel cancer immunotherapies, today announced it will present pre-clinical data regarding its new anti-tumor product candidate during a poster presentation at the 2019 American Association for Cancer Research (AACR) Annual Meeting, which will be held March 29 – April 3, 2019 at the Georgia World Congress Center in Atlanta, Georgia.
The poster is entitled, "Intratumoral administration of plasmid IL-12 and CXCL9 with membrane-bound anti-CD3 elicits robust anti-tumor immunity," and outlines pre-clinical data demonstrating that IL-12, in concert with CXCL9, inflames tumors. This leads to a brisk T cell infiltrate and anti-tumor activity, which when combined with anti-CD3 stimulation, drives a robust systemic T cell response. A link to the abstract of the presentation can be found here.
OncoSec's clinical studies have demonstrated that plasmid IL-12 (tavokinogene telseplasmid) delivered intratumorally (TAVO) induces local expression of IL-12, converting immunologically cold tumors into inflamed immunogenic lesions, which is fundamental to generating objective responses in both treated and untreated distant tumors. In order to identify the key immunological components associated with an effective therapy, OncoSec's research laboratory used immunological findings made from previously treated TAVO patients to design its new, second product candidate.
"This new product candidate builds upon our plasmid-based cancer immunotherapy platform by amplifying the power of intratumoral IL-12 through the addition of both CXCL9, a critical T cell chemokine, along with a membrane bound pan T cell stimulator, anti-CD3," noted Christopher Twitty, Ph.D., Chief Scientific Officer of OncoSec. "Importantly, this new product candidate integrates three key immunotherapeutic elements into a single novel, multi-gene expression platform that we believe has broad applicability across a number of tumor targets. We look forward to filing an Investigational New Drug application for this promising new product."
Presentation details are as follows:
Session Category:
Immunology
Session Title:
Combination Immunotherapies
Presenter:
Anandaroop Mukhopadhyay, PhD, Principal Scientist
Session Date and Time:
April 2, 2019 8:00 A.M – 12:00 P.M.
Poster Board Number:
5
Abstract Number
3195
Location:
Georgia World Congress Center, Exhibit Hall B, Poster Session 23
AI
